Ionis Pharmaceuticals, Inc.

NASDAQ:IONS

Biotechnology

Healthcare
$27.39 +1.67%

+$1.22 today

Market cap
$4.56B
Beta
0.37
P/E (TTM)
-37.5
EPS (TTM)
-$1.98
52W Low $36.45High $86.74

Volume 3.23M

Average 1.83M

IONS Income Tax Expense

Income taxes recognized for the period, including current and deferred tax.

Ionis Pharmaceuticals, Inc.NASDAQ: IONS

Income Tax Expense · Q3 FY2026 · quarter ended Sep 2026

Income tax expense turns negative

Q3 FY2026 income tax expense was -$141K, compared with $213K a year earlier. Trailing-twelve-month income tax expense was -$187K. Over 3 fiscal years it compounded at -56.0% a year.

Context

  • Income tax expense amounted to 0.1% of revenue in FY2025, down 0.8 pp from a year earlier.
  • Income tax expense increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly income tax expense holds near -$141K or moves back toward the trailing-twelve-month quarterly average of -$46.75K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
-$141K+88.8% QoQ
Last fiscal yearDec 2025
$1M+116.2% YoY
LTMSep 2026
-$187K+92.1% YoY
Income Tax Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-166.2%——
1 year+116.2%——
3-year CAGR-56.0%——
5-year CAGR——
10-year CAGR——

Income Tax Expense history

USD · from the income statement

Latest · FY2025
1M USD
Year-over-year change
+116.2%

Income Tax Expense vs competitors

How IONS compares with its peers on the latest reported figures

  • IONS's LTM Sep 2026 income tax expense of -$187K is the 4th highest of the 9 companies compared; the peer median is -$15.12M.
  • Its year-over-year change of +92.1% is the highest of 8, against a peer median of -147.5%.
  • Income tax expense amounts to 0.0% of revenue for IONS, versus a peer median of 0.7%.
IONS Competitors Peer median
Income Tax Expense for IONS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BIIBBiogen Inc.LTM Jun 2026$21.31M -92.0%-44.5%0.2%
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026$3.82M +55.8%-11.1%0.6%
NTLAIntellia Therapeutics, Inc.LTM Mar 2026$0 ——0.0%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026-$187K +92.1%-56.0%0.0%
BBIOBridgeBio Pharma, Inc.LTM Jun 2026-$1.55M -147.5%—0.2%
PTCTPTC Therapeutics, Inc.LTM Jun 2026-$28.69M -177.7%—2.8%
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 2026-$39.75M +34.3%+31.2%0.8%
SRPTSarepta Therapeutics, Inc.LTM Mar 2026-$40.59M -148.2%-6.1%1.9%
BMRNBioMarin Pharmaceutical Inc.LTM Sep 2026-$8.87B -5681.4%+155.4%0.9%
Peer median (excluding IONS) -$15.12M-147.5%-6.1%0.7%

Competitors are the stored peer set for IONS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue810.46M587.37M787.65M705.14M944M
Cost of Revenue10.84M14.12M9.13M11.22M16M
Gross Profit799.61M573.25M778.51M693.92M928M
Gross Margin98.7%97.6%98.8%98.4%98.3%
Research & Development643M833M899.63M901.53M916M
Selling, General & Admin170.9M150.3M232.6M267.5M394M
Operating Expenses829.8M983.44M1.13B1.17B1.31B
Depreciation & Amortization19.56M22.11M22.5M21.99M22.69M
EBITDA(5.19M)(227.76M)(235.87M)(353.72M)(284.31M)
EBITDA Margin-0.6%-38.8%-29.9%-50.2%-30.1%
Operating Income(30.19M)(410.19M)(353.73M)(475.08M)(382M)
Operating Margin-3.7%-69.8%-44.9%-67.4%-40.5%
Interest Income10.04M25.33M89.04M107.02M97.77M
Interest Expense9.35M8.12M81.46M90.45M90.54M
Other Income / Expenses1.04M152.21M19.77M15.01M2M
Income Before Tax(29.15M)(257.99M)(333.97M)(460.07M)(380M)
Pre-Tax Margin-3.6%-43.9%-42.4%-65.2%-40.3%
Income Tax Expense(551K)11.74M32.32M(6.17M)1M
Net Income(28.6M)(269.72M)(366.29M)(453.9M)(381M)
Net Margin-3.5%-45.9%-46.5%-64.4%-40.4%
EPS (Basic)(0.20)(1.90)(2.56)(3.04)(2.38)
EPS (Diluted)(0.20)(1.90)(2.56)(3.04)(2.38)
Weighted Avg Shares141.02M141.85M143M149.51M160M
Weighted Avg Shares (Diluted)141.02M141.85M143.19M149.51M160M

Ionis Pharmaceuticals, Inc.

NASDAQ:IONS

Intrinsic Alpha fair value

Locked

Current Price

$27.39

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.